


DMBA

Cat. No.:	HY-W011845		
CAS No.:	57-97-6		
Molecular Formula:	C ₂₀ H ₁₆		
Molecular Weight:	256.34		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 25 mg/mL (97.53 mM; Need ultrasonic)
 Acetone : 25 mg/mL (97.53 mM; Need ultrasonic)
 Ethanol : 3.33 mg/mL (12.99 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.9011 mL	19.5053 mL	39.0107 mL
	5 mM	0.7802 mL	3.9011 mL	7.8021 mL
	10 mM	0.3901 mL	1.9505 mL	3.9011 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: 2.5 mg/mL (9.75 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2 mg/mL (7.80 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

DMBA has carcinogenic activity as a polycyclic aromatic hydrocarbon (PAH). DMBA is used to induce tumor formation in various rodent models^[1].

In Vivo

DMBA can be used in animal modeling to construct chemically induced skin carcinogenesis, breast cancer and other cancer models.

DMBA (0-150 mg/kg, p.o.) results in a decrease in spleen weight and in the total lymphocytes recovered from the spleen in C57BL/6 mice. DMBA exhibits a terminal deposition half-life of 45 min at all dose ranges (5-50 mg) in SD rats

[5]. DMBA (0-150 mg/kg, p.o.) results in a decrease in spleen weight and in the total lymphocytes recovered from the spleen in C57BL/6 mice. DMBA exhibits a terminal deposition half-life of 45 min at all dose ranges (5-50 mg) in SD rats [5].

1. Induction of breast cancer^[2]

• Background

DMBA activates AhR, which translocates into nucleus and dimerizes with cofactor ARNT, thus induces the expressions of protooncogenes c-myc.

• Specific Modeling Methods

Rat: Sprague-Dawley • female • 750 days • 140-150 g

Administration: 15-20 mg DMBA • intragastric gavage • single dose

Note

1.5-2 g DMBA dissolved in 100 ml sesame oil

• Modeling Indicators

Palpation: Detection of mammary cancer in 150 days.

Histology analysis: The tumor exhibits tightly spaced cords epithelial cells, cysts and papillary structures.

Phenotype: develops a temporary cessation in body growth.

• Opposite Product(s): Phytic acid (HY-N0814); Limonene (HY-N0544)

2. Induction of skin cancer^[3]

• Background

DMBA is metabolized to reactive intermediates, such as syn- and anti-diol epoxides, and binds extensively to epidermal DNA.

• Specific Modeling Methods

European hamster: • 10 weeks • 180-200 g •

Administration: 25 mg DMBA • applied on the shaved back skin • single dose

Note

25 mg DMBA is dissolved in 1 ml acetone

- Modeling Indicators

Histological analysis: Epidermal hyperplasia is observed. Lesions occurred frequently in the back skin, such as trichoeplithelomas, neoplastic epidermal cysts and melanotic tumors

- Opposite Product(s): α -Mangostin (HY-N0328); DHEA (HY-14650); Salidroside (HY-N0109)

3. Induction of lung cancer^[4]

- Background

DMBA is metabolized by cytochrome P450 enzymes into the carcinogenic form 7,12-DMBA-3,4-dihydrodiol-1,2-epoxide, which adducts with DNA and produces mutations.

- Specific Modeling Methods

BALB/c mice: 12 weeks • 25-35 g • 5-20 mg/kg • intratracheal instillation • single dose.

Note

(1). 5-20 mg DMBA is dissolved in 0.2 ml saline.

(2). A coat of antibiotic is applied after the instillation.

- Modeling Indicators

Molecular changes: Increased number of macrophages in the broncho-alveolar lavage (BAL) fluid and levels of malonyldialdehyde (MDA) in lung tissue.

Histology analysis: Inflammation with alveolar epithelial hyperplasia, adenocarcinoma, adenomatoid hyperplasia and atypical hyperplasia.

- Opposite Product(s): Diclofenac (HY-15036)

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. HUGGINS C, et al., Mammary cancer induced by a single feeding of polymucular hydrocarbons, and its suppression. *Nature*. 1961 Jan 21;189:204-7.
- [2]. Goerttler K, et al., Skin tumor formation in the European hamster (*Cricetus cricetus* L.) after topical initiation with 7,12-dimethylbenz[a]anthracene (DMBA) and promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA). *Carcinogenesis*. 1984 Apr;5(4):521-4.
- [3]. Saini RK, et al., Pulmonary carcinogenesis in mice with a single intratracheal instillation of 9, 10-dimethyl benz[a]anthracene. *Drug Chem Toxicol*. 2008;31(4):459-71.
- [4]. Gao J, et al., Microsomal epoxide hydrolase is required for 7,12-dimethylbenz[a]anthracene (DMBA)-induced immunotoxicity in mice. *Toxicol Sci*. 2007 Jul;98(1):137-44.
- [5]. Csiszar A, Balasubramanian P, Tarantini S, Yabluchanskiy A, Zhang XA, Springo Z, Benbrook D, Sonntag WE, Ungvari Z. Chemically induced carcinogenesis in rodent models of aging: assessing organismal resilience to genotoxic stressors in geroscience research. *Geroscience*. 2019 Apr;41(2):209-227.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA